Nintedanib
- Generic Name
- Nintedanib
- Brand Names
- Ofev, Vargatef, Nintedanib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C31H33N5O4
- CAS Number
- 656247-17-5
- Unique Ingredient Identifier
- G6HRD2P839
- Background
Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC). It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis treatment options, nintedanib is currently one of only tw...
- Indication
Nintedanib is indicated for the treatment of idiopathic pulmonary fibrosis (IPF) and to slow declining pulmonary function in patients with systemic sclerosis-associated interstitial lung disease. It is also indicated for the treatment of chronic fibrosing interstitial lung diseases with a progressive phenotype.
...
- Associated Conditions
- Idiopathic Pulmonary Fibrosis (IPF), Respiratory Function Impaired, Chronic Progressive Fibrosing Interstitial Lung Disease, Locally advanced Non-Small Cell Lung Carcinoma (NSCLC), Locally recurrent Non-Small Cell Lung Carcinoma (NSCLC), Metastatic Non-Small Cell Lung Carcinoma (NSCLC)
- Associated Therapies
- -
Myositis Interstitial Lung Disease Nintedanib Trial
- Conditions
- Interventions
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Rohit Aggarwal, MD
- Target Recruit Count
- 70
- Registration Number
- NCT05799755
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸Mayo Clinic Arizona, Scottsdale, Arizona, United States
🇺🇸University of South Florida, Tampa, Florida, United States
Dose Reduction and Discontinuation With Anti-Fibrotic Medications
- First Posted Date
- 2023-03-22
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2778
- Registration Number
- NCT05779007
- Locations
- 🇺🇸
Boehringer Ingelheim, Ridgefield, Connecticut, United States
Safety of Nintedanib in Real World in China
- First Posted Date
- 2023-01-09
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT05676112
A Study to Assess the Effect of AZD5055 on the Pharmacokinetics (PK) of Nintedanib in Healthy Participants.
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 18
- Registration Number
- NCT05644600
- Locations
- 🇬🇧
Research Site, Glendale, United Kingdom
A Treatment Protocol to Support the Care of Children and Adolescents With Fibrosing Interstitial Lung Disease (ILD)
- First Posted Date
- 2022-11-22
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT05624281
Correlation Between Changes in Lung Function and Changes in Cough and Dyspnoea in Nintedanib-treated Connective Tissue Disease Interstitial Lung Disease (CTD-ILD) Patients
- First Posted Date
- 2022-08-16
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 120
- Registration Number
- NCT05503030
- Locations
- 🇬🇷
"ATTIKON" University General Hospital, Athens, Greece
🇬🇷University General Hospital of Heraklion, Heraklion, Greece
🇬🇷University General Hospital of Patra, Patra, Greece
To Evaluate Drug-drug Interactions Between HEC585 and Pirfenidone or Nintedanib in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2022-05-19
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 33
- Registration Number
- NCT05383131
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, China
INCHANGE - Nintedanib for Changes in Cough and Dyspnea in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 160
- Registration Number
- NCT05151640
- Locations
- 🇧🇬
Acibadem CityClinic UMBAL Tokuda Hospital, Sofia, Bulgaria
🇧🇬UMBAL Alexandrovska, Sofia, Bulgaria
🇧🇬MBAL VMA Military Medical Academy, Sofia, Bulgaria
Efficacy & Safety of Nintedanib in Patients With Progressive Fibrosing Coal Mine Dust-Induced Interstitial Lung Disease
- Conditions
- Interventions
- First Posted Date
- 2021-10-05
- Last Posted Date
- 2021-10-05
- Lead Sponsor
- West Virginia University
- Target Recruit Count
- 160
- Registration Number
- NCT05067517
- Locations
- 🇺🇸
West Virginia University Hospital, Morgantown, West Virginia, United States
A Study to Test How Well a Medicine Called Nintedanib Helps People in China With Progressive Lung Fibrosis
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 81
- Registration Number
- NCT05065190
- Locations
- 🇨🇳
China-Japan Friendship Hospital, Beijing, China
🇨🇳The Second Hospital of Jilin University, Changchun, China
🇨🇳First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.